VVUS VIVUS Inc.

3.44
+0.08  (+2%)
Previous Close 3.36
Open 3.4
Price To Book -0.78
Market Cap 36,591,844
Shares 10,637,164
Volume 1,800
Short Ratio
Av. Daily Volume 46,975

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved July 17, 2012.
Qnexa
Obesity
Approved Apr 27 2012. sNDA label change also approved 17 Sept 2014
Avanafil
Erectile dysfunction
Phase 1 trial completed July 2018.
VI-0106
Pulmonary arterial hypertension (PAH)

Latest News

  1. Does The VIVUS, Inc. (NASDAQ:VVUS) Share Price Fall With The Market?
  2. VIVUS Reduces Barrier to Achieving Healthy Weight Goals With Launch of Online Platform to Purchase Qsymia®
  3. VVUS: Qsymia Receives an FDA Letter
  4. VIVUS Initiates Phase Four Safety and Efficacy Study of Qsymia® in Obese Adolescents
  5. VIVUS Partners with HarborPath Direct to Facilitate Access to PANCREAZE® for Patients Without Health Insurance
  6. VVUS: New Ideas for Established Portfolio
  7. Edited Transcript of VVUS earnings conference call or presentation 30-Apr-19 8:30pm GMT
  8. Vivus: 1Q Earnings Snapshot
  9. VIVUS Reports First Quarter 2019 Financial Results
  10. If You Had Bought VIVUS (NASDAQ:VVUS) Stock Five Years Ago, You'd Be Sitting On A 93% Loss, Today
  11. VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Tuesday, April 30, 2019
  12. VIVUS Announces Marketing Approval of Avanafil in the Russian Federation for the Treatment of Erectile Dysfunction
  13. Edited Transcript of VVUS earnings conference call or presentation 26-Feb-19 9:30pm GMT
  14. VIVUS Reports Fourth Quarter 2018 Financial Results
  15. VIVUS to Host Fourth Quarter and Full Year Business Update and Financial Results Conference Call on Tuesday, February 26, 2019
  16. 3 Biotech Stocks That Pay Solid Dividends
  17. VIVUS Announces Date of 2019 Annual Meeting
  18. Today's Research Reports on Trending Tickers: Array BioPharma and VIVUS
  19. Data Supporting the Cardiovascular Safety of VIVUS’ Qsymia® Published in The Journal of Clinical Endocrinology & Metabolism
  20. VIVUS (VVUS) Banks on New Drug Pancreaze, Qsymia Lacks Luster